Login to Your Account



Portola into the future: APEX factor Xa phase III to proceed

By Randy Osborne
Staff Writer

Friday, February 6, 2015

Going it alone with the oral, once-daily factor Xa inhibitor betrixaban, for which Merck & Co. Inc. handed back rights in 2011, Portola Pharmaceuticals Inc. marches ahead.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription